First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat
Gesynta Pharma AB has announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for endometriosis. This milestone marks an important step toward a …